7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Gut Health

What Remission Looks Like in Autoimmune Hepatitis and Why Monitoring Continues

23 min read
What Remission Looks Like in Autoimmune Hepatitis and Why Monitoring Continues

Key Takeaways

  • Remission in autoimmune hepatitis is defined by normal ALT and IgG levels and, where tissue is examined, minimal inflammation; symptoms and autoantibody results are not part of the definition.
  • Biochemical remission measured in blood can occur before inflammation fully settles inside the liver, which is why teams often want biopsy or scan evidence before considering any withdrawal of medicine.
  • Corticosteroids act within days to weeks while thiopurines take months, so treatment plans are designed to shift weight from the fast, broad medicine to the slower, steroid-sparing one.
  • Consumer guidance from the NIDDK and Mayo Clinic describes treatment as often lifelong, with any trial off medicine usually considered only after several years of sustained, complete remission.
  • Type 2 autoimmune hepatitis, marked by anti-LKM1 antibody and mostly diagnosed in children, is associated with particularly frequent relapse after stopping treatment, so lifelong maintenance is the usual approach.
  • Relapses are typically detected in blood before any symptoms appear, which makes scheduled testing the single most protective habit for anyone in remission, on or off medicine.
Quick Answer

Autoimmune hepatitis remission means the immune attack on the liver has quieted: liver enzymes and immunoglobulin G return to normal, and a biopsy, if taken, shows little or no active inflammation. Remission is a controlled state rather than a resolved disease. Because the condition can flare again, especially after medicine is reduced or stopped, blood tests and specialist reviews continue for life.

The letter from the liver clinic is short. Two lines of numbers, both sitting inside the normal range for the first time in a year, and a single word underlined by the nurse: remission. You read it on the bus, then again in the kitchen, and the question that follows is not the one you expected. Not “is it over?” but “why am I still being asked back in three months?”

That tension sits at the heart of autoimmune hepatitis remission. It is real, it is measurable, and it changes how you feel and how your liver ages. Yet it does not switch the condition off. The immune system that mistook liver cells for intruders has been persuaded to stand down, not retrained.

This explainer walks through what remission means in plain terms, how clinicians decide it has been reached, why some people are offered a supervised trial off medicine while others are asked to wait, and what the years of quiet monitoring are actually for.

What is the rare autoimmune disease that attacks the liver?

Autoimmune hepatitis is a long-term condition in which the body’s own immune system inflames the liver. “Hepatitis” simply means liver inflammation; the “autoimmune” part signals that the trigger is not a virus, alcohol or a medicine, but a misdirected defense response. Immune cells infiltrate the liver, injure hepatocytes (the working cells that filter blood and make proteins), and, if unchecked, leave scar tissue behind.

It is uncommon. The National Institute of Diabetes and Digestive and Kidney Diseases describes it as a rare disease that is more frequent in women than men and can begin at any age, from childhood to later life. Many people are diagnosed after routine bloodwork shows raised liver enzymes with no obvious cause; others arrive with fatigue, joint aches or jaundice, a yellowing of the skin and eyes caused by bilirubin building up.

Diagnosis rests on a pattern rather than a single test. Clinicians look at the level and behavior of liver enzymes, at immunoglobulin G (IgG, an antibody protein that tends to run high when the liver is under autoimmune attack), at autoantibodies such as antinuclear antibody or smooth muscle antibody, and usually at a liver biopsy, a small tissue sample examined under a microscope. Viral hepatitis and other causes must be ruled out first.

Why does this matter for a conversation about remission? Because the same markers used to confirm the diagnosis are the ones that later define whether the disease is quiet. Remission, in other words, is measured with the very tools that found the problem, which is why the blood forms keep arriving long after you feel well.

What does autoimmune hepatitis remission actually mean?

In everyday language, remission sounds like an ending. In hepatology it is a definition with parts. Autoimmune hepatitis remission is usually described as the point at which liver enzymes (particularly alanine aminotransferase, or ALT, an enzyme that leaks from injured liver cells) and IgG have both returned to the normal range, and any liver tissue sampled shows no more than minimal inflammation.

Doctor consulting patient about diet with salad bowl: What does autoimmune hepatitis remission actually mean?

Each element carries a different message. Normal enzymes tell you that cells are no longer being damaged at a rate the blood can detect. Normal IgG suggests the antibody-producing arm of the immune system has calmed. A quiet biopsy confirms that what the blood implies is true inside the organ.

Notice what is not on that list. Symptoms are not a criterion, because autoimmune hepatitis can smolder without any, and fatigue can persist after the numbers normalize. Autoantibodies are not a criterion either; they often remain detectable for years in people whose disease is fully controlled, and their titer is a poor guide to activity. Mayo Clinic and the NIDDK both frame remission as a treatment goal that most people reach with immunosuppression, while stressing that the underlying tendency remains.

Clinicians sometimes speak of “complete” versus “incomplete” response. An incomplete response means the numbers have improved but not normalized, and the team will usually adjust the plan rather than declare victory. That nuance matters, because research summarized by consumer health sources suggests that people whose enzymes settle only partway carry a higher long-term risk of progressive scarring than those who reach full normalization. The target, wherever safely achievable, is all the way back to normal.

Biochemical remission vs histological remission: why the distinction matters

Two phrases appear on clinic letters and in research papers, and they are not interchangeable. Biochemical remission of autoimmune hepatitis is judged from blood: normal ALT, normal aspartate aminotransferase (AST, a related enzyme) and normal IgG. Histological remission is judged from tissue: a biopsy showing no or minimal inflammatory activity.

Blood lags tissue. Enzymes can normalize while a low level of inflammation continues inside the liver, which is one reason some teams repeat a biopsy before any attempt to withdraw medicine. Conversely, a biopsy sample is tiny, and inflammation is patchy, so a quiet sample is reassuring but not absolute.

Type of remission How it is measured What it tells you Limitations
Biochemical Blood tests: ALT, AST, IgG Cell injury and antibody activity have fallen to undetectable levels in blood Can normalize before tissue inflammation fully settles
Histological Liver biopsy Direct view of inflammation and scarring inside the organ Invasive; samples a small area; not repeated often
Sustained (off treatment) Normal blood tests months to years after medicine stops Disease is quiet without drug suppression Relapse remains possible at any point

Non-invasive scans that estimate liver stiffness are increasingly used between biopsies to track scarring, though they measure fibrosis rather than inflammation and are interpreted alongside blood results rather than instead of them.

Why should a patient care about the vocabulary? Because a letter saying “biochemical remission” is good news with a footnote. It means the plan is working. It does not yet mean the plan can end. Understanding which kind of remission has been reached helps make sense of why the next step might be “continue and recheck” rather than “stop.”

How treatment works to bring autoimmune hepatitis into remission

The strategy is to dampen the immune system enough to stop it injuring the liver, then keep it dampened with the smallest footprint that holds. Two classes of medicine do most of the work, and they act at different speeds.

Doctor consulting patient about diet and nutrition: How treatment works to bring autoimmune hepatitis into remission

Corticosteroids are the fast brake. They suppress inflammation broadly, reducing the activity of the immune cells infiltrating the liver within days to weeks. According to the NIDDK, a corticosteroid is typically the first medicine started, precisely because it works quickly. Its drawback is the breadth of its effect: over months it can raise blood sugar, thin bones, disturb sleep and mood, and change body weight and fat distribution. Nobody wants to stay on a high level of steroid for long.

A thiopurine, most commonly azathioprine, is the slow steady hand. It interferes with the building blocks that rapidly dividing immune cells need to multiply, so it takes weeks to months to reach full effect. Its purpose is to allow the steroid to be reduced while remission holds. Before or soon after starting, many teams check an enzyme called TPMT, which affects how a person processes the drug, and they monitor blood counts and liver tests closely because the medicine can lower white cells or, less often, irritate the liver itself.

When these first-line options are not tolerated or not enough, clinicians may consider other immunosuppressant classes. Those decisions are individualized and sit entirely with the prescribing team.

The principle to hold onto is this: treatment does not repair the immune system’s mistake. It suppresses the consequence. Remove the suppression and, for most people, the mistake reasserts itself, which is the mechanistic reason monitoring never fully ends.

How long does it take to reach remission, and what the first months look like?

The early phase is busy. Blood is drawn frequently, often every couple of weeks at first, so the team can watch enzymes fall and catch any side effects early. Mayo Clinic notes that many people notice enzyme improvement within the first weeks of treatment, with full normalization taking longer.

A typical arc, described in consumer guidance from the NIDDK and Mayo Clinic, runs like this. In the first weeks, the corticosteroid pulls inflammation down and energy often begins to return. Over the following months, the slower immunosuppressant takes hold and the steroid is gradually reduced under supervision. Biochemical remission is commonly reached within the first year, although the range is wide, and some people take longer or need adjustments along the way.

Fatigue is worth a specific mention. Liver numbers frequently normalize before stamina does, and many people describe a frustrating gap between “the tests say fine” and “I feel fine.” That gap is common and does not by itself mean treatment is failing.

Side effects shape the timeline too. Steroid-related sleep disturbance, mood change and appetite shifts tend to be most pronounced early and ease as the level comes down. Thiopurine-related nausea or low blood counts, when they occur, usually surface in the first weeks to months, which is why blood counts are checked alongside liver tests.

Once remission is confirmed, testing spaces out. The NIDDK describes ongoing checks every few months while on maintenance treatment. Nothing about the schedule is fixed; it flexes with results, side effects and life events, and every change to medicine is a decision made with the prescribing clinician rather than in response to a single good result.

Who is usually offered a trial off treatment, and who is asked to wait?

Stopping medicine is not a reward for good numbers. It is a controlled experiment with a known risk of relapse, and teams choose candidates carefully.

The people most often considered are those who have held complete biochemical remission, normal enzymes and normal IgG, for a sustained period. The NIDDK indicates that clinicians may consider stopping treatment after remission has been maintained for several years, commonly at least two, and many hepatologists want a recent biopsy or equivalent evidence showing no residual inflammation first. A stable, low level of scarring, or none, weighs in favor. So does having reached remission smoothly on standard treatment.

Others are usually asked to wait, or advised that lifelong maintenance is the safer path:

  • People who have relapsed before when medicine was reduced. A prior relapse strongly predicts another.
  • People with cirrhosis, the advanced scarring stage, in whom a flare has less reserve to fall back on.
  • People whose IgG or enzymes have drifted above normal, even slightly, during maintenance.
  • Children and adults with type 2 disease, where relapse after withdrawal is described by Mayo Clinic as particularly common.
  • People who needed second-line medicines to reach remission in the first place.

Age, other medical conditions, planned pregnancy and personal preference all enter the conversation. Some people who qualify for a trial choose to stay on a low maintenance level because the certainty suits them; others accept the risk of a flare for the chance of drug-free years. Both are legitimate. What guidelines caution against is unsupervised stopping, because a relapse caught late can be considerably more severe than the original presentation.

Does autoimmune hepatitis ever go away?

Ask a hepatologist and you will likely hear a careful answer: the inflammation can be brought fully under control, and in a minority of people it stays controlled after medicine stops, but the underlying autoimmune tendency is considered lifelong. Mayo Clinic puts it plainly, noting that although some people can eventually stop treatment, the disease often returns.

Why the pessimism about spontaneous disappearance? Autoimmune hepatitis arises from a combination of genetic susceptibility and an environmental trigger that clinicians usually cannot identify. The susceptibility does not leave. The immune “memory” that learned to target liver antigens persists. Suppressing the response for years may reduce its momentum, but it does not erase the lesson.

That said, the phrase “does autoimmune hepatitis go away” hides two different questions. If the question is “will I always have inflamed liver cells and abnormal tests?”, the answer for most treated people is no. Remission is achievable and often durable. If the question is “will I ever be able to stop thinking about it?”, the honest answer is also no, though the amount of thinking shrinks to a few blood tests and appointments a year.

There is a hopeful nuance. People who do achieve sustained remission off treatment, sometimes for many years, exist in every large cohort described in the medical literature. Clinicians cannot reliably predict in advance who they will be, which is exactly why the trial-off-treatment process is slow, structured and monitored rather than guessed at.

So the disease does not go away in the way an infection does. What can go away, with treatment and time, is the damage it causes and the daily weight of it.

What is type 2 autoimmune hepatitis, and does remission look different?

Autoimmune hepatitis is divided into two types based on the autoantibodies found in the blood. Type 1, by far the more common, is marked by antinuclear antibody or smooth muscle antibody and can appear at any age. Type 2 autoimmune hepatitis is defined by a different antibody, anti-liver-kidney microsomal type 1 (anti-LKM1), and, as Mayo Clinic and Cleveland Clinic describe, it is diagnosed mostly in children and young adults, and is rarer overall.

The distinction is not academic. Type 2 tends to present more abruptly, sometimes with an acute, jaundiced illness, and it more often coexists with other autoimmune conditions such as type 1 diabetes or thyroid disease. It also behaves differently once controlled. Guidance from Mayo Clinic notes that people with type 2 disease usually need lifelong treatment because relapse after stopping is especially frequent.

For remission, the definition is the same: normal enzymes, normal IgG, quiet tissue. What changes is the strategy afterwards. Teams caring for someone with type 2 disease tend to aim for the lowest maintenance level that holds remission rather than planning for withdrawal. In children, growth and bone development add further reasons to minimize steroid exposure and lean on steroid-sparing medicines once remission is established.

Families often ask whether a child will “grow out of it.” The available evidence does not support that expectation, and adolescence brings its own challenge: this is the age when medicine is most often missed or quietly stopped, and pediatric liver services report flares clustering around that transition. Preparing a young person to own their monitoring, rather than have it done to them, is part of the treatment plan.

Whichever type is present, the practical message converges: remission is the goal, monitoring is the routine, and the type informs how cautious the team will be about letting go.

Why monitoring continues after autoimmune hepatitis remission

Monitoring in remission is not a sign of doubt about the diagnosis or the treatment. It serves four separate purposes, and each would justify the blood form on its own.

The first is detecting relapse early. A flare usually announces itself in the blood before it produces symptoms, often as a modest rise in ALT or IgG. Caught at that stage, it can frequently be settled with an adjustment rather than a restart from scratch. Caught late, after weeks of unchecked inflammation, it can cause jaundice and add permanent scar.

The second is safety monitoring of the medicines themselves. Thiopurines can lower white cell counts and, over years, are associated with a modestly higher risk of certain skin cancers and lymphoma, which is why periodic blood counts and skin awareness are routine. Long-term steroid exposure calls for bone density assessment and attention to blood sugar and blood pressure.

The third is tracking the liver’s structural health. Inflammation is what treatment controls; scarring is what it aims to prevent. Scans that estimate stiffness, along with platelet counts and albumin, help the team judge whether fibrosis is stable, improving or quietly progressing.

The fourth applies to people who already have cirrhosis. Advanced scarring carries a risk of liver cancer and of complications such as enlarged veins in the esophagus, so surveillance ultrasound, described by Mayo Clinic as part of ongoing care in cirrhosis, is typically scheduled at regular intervals, often every six months, alongside checks for portal hypertension.

Frequency varies with circumstances. Someone stable on long-term maintenance without cirrhosis may be seen a few times a year; someone in the first year after stopping medicine will be tested far more often. The schedule is a clinical judgment, revisited at each visit.

Autoimmune hepatitis relapse after stopping treatment: what the evidence shows

Relapse is the central fact around which every withdrawal decision is built. Mayo Clinic states that after treatment is stopped, the disease often returns, and it is candid that relapse is common even in people who met every criterion for a trial. Published cohorts summarized in the hepatology literature report that a majority of people who stop medicine eventually flare, with the highest risk in the first year or two and a smaller ongoing risk thereafter. Exact figures vary widely between studies depending on how strictly remission was defined before withdrawal.

What predicts a flare? Several patterns recur across the evidence:

  • Incomplete normalization before stopping, particularly an IgG still in the upper normal range.
  • Persistent inflammation on biopsy despite normal blood tests.
  • A shorter duration of remission before withdrawal.
  • Type 2 disease and younger age at diagnosis.
  • A previous relapse.

Relapses are usually detected through routine testing rather than symptoms, which is the strongest argument for keeping appointments during a trial off treatment. Most are managed by reintroducing the same class of medicine that worked before, and remission is usually regained. After a second relapse, guidelines generally advise long-term maintenance rather than another withdrawal attempt.

It helps to reframe what a relapse means. It is not a failure of willpower, diet or discipline. It is the expected behavior of an autoimmune condition when suppression is lifted, and the trial off treatment was designed with that possibility priced in. People who relapse and return to maintenance have lost little if the flare was caught early; what they have gained is certainty about which path suits their disease.

Unsupervised stopping is the scenario clinicians worry about. Missed doses over holidays, a pharmacy gap, or a decision to “see what happens” can produce a flare without the safety net of scheduled testing.

What people often get wrong about remission

Myths gather around any condition that is rare and long-term. These are the ones hepatology teams hear most, and what the evidence says instead.

“Normal liver tests mean I can stop the medicine.” Normal tests mean the medicine is working. Stopping is a separate decision that depends on how long remission has held, what a biopsy or scan shows, and the type of disease. The NIDDK and Mayo Clinic both describe treatment as often lifelong.

“My antibodies are still positive, so I’m not really in remission.” Autoantibodies commonly persist in well-controlled disease and are not used to define remission. Enzymes and IgG are the markers that matter.

“I feel fine, so I don’t need the blood tests.” Flares are usually silent at first. The blood test is how they are caught before symptoms and before scar.

“A liver-cleansing diet or supplement can replace treatment.” No dietary regimen or supplement has been shown to control autoimmune liver inflammation. Some herbal products are themselves associated with liver injury, so anything new should be run past the team.

“Autoimmune hepatitis is contagious or caused by something I did.” It is not infectious and is not caused by alcohol, diet or lifestyle. Genetic susceptibility plus an unidentified trigger is the accepted model.

“Once I have cirrhosis, treatment is pointless.” Controlling inflammation still matters at every stage; it can slow further scarring and reduce complications. Monitoring simply becomes more intensive.

“Remission means the liver has fully healed.” Inflammation can resolve while some scarring remains. Scar can soften over years of quiet disease, and stiffness scans sometimes improve, but the extent varies from person to person and cannot be promised.

Living well in remission: bones, vaccines, alcohol and planning ahead

Remission opens space for ordinary life, and a few practical habits make the years of maintenance smoother.

Bone health. Corticosteroids accelerate bone loss, and chronic liver disease adds its own risk. Weight-bearing activity, adequate calcium and vitamin D from diet or as advised by the team, and periodic bone density scans are standard parts of long-term care. Any supplement decision, including vitamin D, belongs with the prescribing clinician, since liver disease can change how nutrients are handled.

Vaccination. People on immunosuppression are more vulnerable to infection and respond less robustly to some vaccines. Hepatitis A and B vaccination is generally recommended for anyone with chronic liver disease, and live vaccines are usually avoided during immunosuppressive treatment. Discuss timing with the team; some vaccines are best given before a medicine starts.

Alcohol. Alcohol did not cause the condition, but it adds a second source of liver injury on top of an autoimmune one. Most hepatology guidance advises minimizing or avoiding it, particularly where any scarring is present.

Infections and new medicines. Tell any clinician you see that you take an immunosuppressant. Some antibiotics and other drugs interact with thiopurines, and an unexplained fever on immunosuppression warrants prompt assessment rather than a wait-and-see approach.

Pregnancy. Many people with well-controlled autoimmune hepatitis have healthy pregnancies. Flares can occur, particularly in the months after delivery, so pregnancy is best planned with the liver team, who will review which maintenance options are appropriate and set a monitoring schedule through and after pregnancy.

Skin. Long-term thiopurine use is linked to a higher risk of skin cancer. Sun protection and reporting new or changing skin lesions are simple, evidence-based precautions.

Questions to ask your care team about autoimmune hepatitis remission

Appointments are short and the questions that matter tend to surface on the drive home. Bringing a written list turns a review into a conversation. These are the ones hepatology nurses say patients find most useful.

  • Which of my results define remission for me, and where do they sit right now relative to normal?
  • Am I in biochemical remission only, or do we have tissue or scan evidence that inflammation has settled?
  • Is there any scarring, and is it stable, improving or progressing on recent scans?
  • What is my current maintenance plan designed to achieve, and what would prompt you to change it?
  • Am I someone you would ever consider for a supervised trial off treatment? If not, what factors weigh against it?
  • If we did try stopping, how often would I be tested, and for how long?
  • What early signs, in blood or in how I feel, would make you want to see me sooner?
  • Which vaccines should I have, and does any need to be timed around my medicine?
  • How often should my bone density, blood counts and skin be checked?
  • Are there medicines, supplements or herbal products I should specifically avoid?
  • If I am planning a pregnancy, when should that conversation start?
  • Who do I contact between appointments if I develop jaundice, a fever or dark urine?

Two habits make these questions land. First, ask for your actual numbers rather than “fine”; most clinics will share ALT and IgG values, and tracking them over time gives you a sense of your own baseline. Second, ask what the plan is for the next twelve months, not just the next appointment. Remission care is a long game, and understanding the shape of it reduces the anxiety that a single unexpected result can provoke.

When to call your doctor

Most of the time, remission is uneventful. The blood tests come back normal, the appointment is brief, and life carries on. A small number of changes, though, should not wait for the next scheduled review. Contact your liver team promptly, or seek urgent care if the team is unavailable, if you notice any of the following.

  • Yellowing of the skin or the whites of the eyes, which suggests bilirubin is rising and inflammation may have returned.
  • Dark, tea-colored urine or pale, clay-colored stools, both of which can accompany jaundice.
  • New or worsening pain or tenderness under the right ribs.
  • Fever, chills or an infection that is not settling, particularly while taking an immunosuppressant, which can blunt the body’s ability to fight it.
  • Unusual bruising, bleeding gums or nosebleeds, which may signal a fall in platelets or white cells, or a change in the liver’s clotting function.
  • Sudden swelling of the abdomen or legs, or shortness of breath.
  • Confusion, unusual drowsiness or a change in personality, which in someone with liver disease can indicate toxins building up and requires emergency assessment.
  • Vomiting blood or passing black, tarry stools, which are emergencies.
  • Severe fatigue, nausea or itching that is new and persistent rather than a passing bad day.

Also call before, not after, making any change to your medicine, including pausing it because of a stomach upset, a pharmacy gap or a new prescription from another clinician. A missed stretch of treatment is one of the most common triggers for a flare, and the team can usually advise quickly on how to handle it.

None of these signs confirms a relapse on its own, and several have other explanations. The point of calling is to let the people who know your disease decide what the change means, ideally with a blood test, rather than to wait and see.

Frequently asked questions

Does autoimmune hepatitis ever go away completely?

The inflammation can be brought fully under control, but the underlying autoimmune tendency is considered lifelong. Mayo Clinic notes that while some people eventually stop medicine, the disease often returns. A minority maintain remission for years without treatment, yet clinicians cannot reliably predict who, so any withdrawal is gradual, supervised and followed by long-term blood monitoring rather than treated as a final discharge.

Can you live 30 years or more with autoimmune hepatitis?

Autoimmune hepatitis is managed as a long-term, controllable condition, and consumer health sources such as the NIDDK and Mayo Clinic describe most people responding to treatment and living full lives. Outlook depends heavily on how early inflammation is controlled and whether cirrhosis is present at diagnosis. Individual prognosis is a conversation for your own liver team, who can interpret your scans, blood tests and treatment response.

What is type 2 autoimmune hepatitis?

Type 2 autoimmune hepatitis is the rarer form, defined by anti-liver-kidney microsomal type 1 (anti-LKM1) antibody in the blood. It is diagnosed mostly in children and young adults, can begin abruptly, and often coexists with other autoimmune conditions. Remission is defined the same way as in type 1, but because relapse after stopping treatment is especially common, lifelong maintenance is usually recommended.

What does biochemical remission in autoimmune hepatitis mean?

Biochemical remission means blood tests have normalized: liver enzymes such as ALT and AST are within the normal range, and immunoglobulin G has returned to normal. It shows treatment is working but does not prove that all inflammation inside the liver has settled, since tissue can lag blood. Teams may seek biopsy or scan evidence, called histological remission, before considering any change to maintenance medicine.

How often is autoimmune hepatitis relapse after stopping treatment?

Relapse is common. Mayo Clinic states that the disease often returns after treatment stops, and published cohorts indicate that a majority of people who withdraw medicine eventually flare, most within the first year or two. Risk is higher with incomplete normalization before stopping, residual inflammation on biopsy, type 2 disease or a previous relapse. Relapses are usually caught by routine blood tests and settled by restarting the same class of medicine.

Why do I still need blood tests if I am in remission?

Because flares are usually silent at first and show up in blood before symptoms, allowing early adjustment rather than a full restart. Tests also monitor medicine safety, particularly blood counts on thiopurines, and track whether liver scarring is stable. People with cirrhosis need additional surveillance for complications. The interval is set by your team and typically lengthens once remission has been stable for some time.

Do positive autoantibodies mean my autoimmune hepatitis is active?

No. Antinuclear, smooth muscle or anti-LKM1 antibodies often remain detectable for years in people whose disease is fully controlled, and their level is a poor guide to activity. Remission is judged by liver enzymes, immunoglobulin G and, where available, liver tissue or stiffness scans. If your antibodies are positive but those markers are normal, that pattern is consistent with well-controlled disease.

Can autoimmune hepatitis remission be maintained without medication?

For some people, yes, after a carefully supervised withdrawal, but it is not the majority experience. Candidates usually have several years of complete biochemical remission and evidence of quiet liver tissue, and they are monitored closely afterwards. Type 2 disease, cirrhosis, prior relapse and incomplete normalization generally lead teams to recommend continued maintenance. No diet, supplement or lifestyle change has been shown to replace immunosuppressive treatment.

What happens if I miss doses or stop my autoimmune hepatitis medicine on my own?

Unsupervised stopping is the scenario clinicians most want to avoid, because a flare can develop without the safety net of scheduled testing and may be more severe than the original illness. If you have missed doses for any reason, including illness or a pharmacy gap, contact your liver team promptly for advice. Do not adjust, pause or restart medicine without their guidance.

Does remission mean my liver has healed from scarring?

Not necessarily. Remission describes the absence of active inflammation, while scarring, or fibrosis, is the damage inflammation leaves behind. Some scar can soften over years of quiet disease and stiffness scans sometimes improve, but the degree varies and cannot be promised. Your team will track fibrosis over time with scans and blood markers, and if cirrhosis is present, monitoring for its complications continues regardless of remission.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 20, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.